Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Treatment of preeclampsia and eclampsia,Treatment of hypomagnesemia,Prevention of seizures in severe preeclampsia,Management of ventricular arrhythmias (torsades de pointes),Acute nephritis in children (off-label),Cerebral edema (off-label)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Magnesium is not metabolized; it is primarily excreted unchanged by the kidneys via glomerular filtration and tubular reabsorption. Elimination half-life is approximately 4-6 hours in normal renal function.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Approximately 25-30% bound to albumin.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
0.2-0.3 L/kg; distributes primarily in extracellular fluid.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
IV: 100%. Not administered orally for systemic effect due to poor GI absorption (<30%).
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
GFR 30-50 m L/min: reduce dose by 50% and monitor serum magnesium; GFR <30 m L/min: contraindicated or use extreme caution with dose reduction to 25% of normal and frequent monitoring.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
Child-Pugh A (mild): no specific adjustment; Child-Pugh B (moderate): use with caution, consider dose reduction; Child-Pugh C (severe): avoid use or reduce dose by 50% with close monitoring of magnesium levels and renal function.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Loading dose: 20-40 mg/kg intravenously over 1-2 hours; maintenance: 10-20 mg/kg IV every 4-6 hours as needed; maximum infusion rate 150 mg/min; monitor serum magnesium during therapy.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Reduce initial dose by 25-50% due to age-related decline in renal function; monitor serum magnesium and renal function closely; adjust dose based on GFR and clinical response.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
WARNING: Do not administer undiluted intravenously. Continuous monitoring of serum magnesium levels, respiratory rate, deep tendon reflexes, and urine output is required. Hazardous infusion rates may cause respiratory arrest, cardiac arrest, or death.
None
May cause respiratory depression or arrest if given too rapidly or in excessive doses.,Use with caution in patients with renal impairment due to risk of accumulation and toxicity.,Administer IV with caution in patients receiving digitalis glycosides; may cause heart block.,Monitor deep tendon reflexes, respiratory rate, and urine output during infusion.,Avoid concurrent use of neuromuscular blocking agents; may potentiate blockade.,Use with caution in patients with myasthenia gravis or other neuromuscular disorders.,Risk of hypotension, flushing, and bradycardia with rapid IV administration.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to magnesium sulfate or any component of the formulation,Myocardial damage or heart block (unless used for torsades de pointes),Severe renal impairment (anuria or oliguria) without dialysis,Comatose patients (unless for seizure control),Absence of deep tendon reflexes (sign of hypermagnesemia)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
Avoid high-calcium or high-phosphate foods that may interfere with magnesium absorption. Limit alcohol and caffeine. No specific dietary restrictions beyond general healthy diet.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Magnesium sulfate crosses the placenta and is not associated with major teratogenic effects when used for standard obstetric indications. Prolonged exposure (e.g., >5-7 days) in the second/third trimester may cause fetal hypocalcemia, skeletal abnormalities, or neonatal hypotonia. Continuous infusion near delivery may lead to neonatal respiratory depression and flaccidity.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Magnesium sulfate is excreted into breast milk in low amounts; M/P ratio approximately 0.2-0.3. Usually compatible with breastfeeding but monitor infant for hypotonia, lethargy, or feeding difficulties if high maternal doses are used long-term.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy may increase renal clearance and volume of distribution, potentially requiring higher loading or maintenance doses to achieve therapeutic levels for seizure prophylaxis/prevention. However, standard dosing protocols (e.g., 4-6 g loading, 1-2 g/h maintenance) are typically effective; adjust based on serum magnesium monitoring and renal function.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Monitor serum magnesium levels closely, especially in renal impairment. Infusion site reactions (phlebitis) may occur; use central line for prolonged therapy. Calcium gluconate should be available as antidote for magnesium toxicity. Assess deep tendon reflexes before and during infusion; loss of patellar reflex indicates impending toxicity. Correct hypokalemia and hypocalcemia concomitantly to enhance magnesium retention.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Report any flushing, sweating, or feeling of warmth during infusion.,Do not stop the medication abruptly; dose tapering may be needed.,Inform your doctor if you have kidney disease or are taking diuretics.,Avoid alcohol and caffeine, which can worsen electrolyte imbalances.,Stay hydrated but follow fluid restrictions if advised by your doctor.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Felbamate, an antiepileptic drug, potentiates the central nervous system (CNS) depressant effects of magnesium sulfate, a tocolytic and anticonvulsant agent. This additive pharmacodynamic interaction can lead to excessive sedation, respiratory depression, and impaired motor coordination. Clinically, concurrent use may exacerbate hypotonia, hyporeflexia, and somnolence, particularly in patients with renal impairment or those receiving high doses."
"Coadministration of Clevidipine, a dihydropyridine calcium channel blocker, and Magnesium sulfate, which acts as a physiological calcium antagonist, potentiates the hypotensive and negative inotropic effects due to additive inhibition of calcium influx into cardiac and vascular smooth muscle cells. This can lead to exaggerated reductions in blood pressure, bradycardia, and impaired cardiac contractility, particularly in patients with pre-existing cardiovascular compromise. Severe hypotension and heart block have been reported, especially during intravenous administration of both agents."
"The combination of nicardipine, a calcium channel blocker, and magnesium sulfate, a calcium antagonist, synergistically reduces vascular smooth muscle contractility and myocardial conduction. This additive pharmacodynamic effect can lead to profound hypotension, bradycardia, and impaired cardiac contractility, particularly in patients with pre-existing cardiovascular compromise. Clinically, patients may experience symptomatic hypotension, dizziness, or syncope, and in severe cases, cardiovascular collapse may occur."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte that works by Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER is: 1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Magnesium sulfate crosses the placenta and is not associated with major teratogenic effects when used for standard obstetric indications. Prolonged exposure (e.g., >5-7 days) in th. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.